Accurately delivering drugs to the retina has long been a problem; both eye drops and intravitreal injections rely on passive diffusion – inherently random and typically slow – to make sure medications reach the target. This limits dose accuracy and the speed at which medicines can be administered to the retina.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The College has issued guidance, following the recent MHRA drug safety update, which has drawn attention to a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION) associated with weight loss drugs.